<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1026">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147792</url>
  </required_header>
  <id_info>
    <org_study_id>21-101</org_study_id>
    <nct_id>NCT05147792</nct_id>
  </id_info>
  <brief_title>The CONFORM Pivotal Trial</brief_title>
  <official_title>An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conformal Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conformal Medical, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CLAAS™ device will be evaluated for safety and efficacy by establishing its performance&#xD;
      is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage&#xD;
      closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible&#xD;
      for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or&#xD;
      Amulet™ devices and will be followed for 5 years after device implant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">March 2030</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure-related complications, all-cause death, major bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>The primary safety endpoint is a composite of procedure-related complications, or all cause death, or major bleeding through 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemic stroke and systemic embolism</measure>
    <time_frame>18 months</time_frame>
    <description>The primary effectiveness endpoint is a composite of ischemic stroke and systemic embolism through 18 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major procedure-related complications</measure>
    <time_frame>45 days</time_frame>
    <description>A composite of cardiac perforation, pericardial effusion requiring drainage, ischemic stroke, device embolization, and major vascular complications through 45 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major safety events</measure>
    <time_frame>18 months</time_frame>
    <description>A composite of all-cause mortality, overt CNS injury (NeuroARC defined), and major bleeding (BARC Type 3-5) through 18 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Closure success</measure>
    <time_frame>45 days</time_frame>
    <description>Closure or peri-device residual leak &lt;5 mm in width on transesophageal echocardiogram (TEE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>CLAAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter left atrial occluder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WATCHMAN / Amulet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcatheter left atrial occluder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conformal Left Atrial Appendage Seal</intervention_name>
    <description>Conformal Left Atrial Appendage Seal</description>
    <arm_group_label>CLAAS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder</intervention_name>
    <description>WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder</description>
    <arm_group_label>WATCHMAN / Amulet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant female aged ≥18 years&#xD;
&#xD;
          2. Documented non-valvular AF (paroxysmal, persistent, or permanent)&#xD;
&#xD;
          3. High risk of stroke or systemic embolism, defined as CHADS2 score of &gt;2 or&#xD;
             CHA2DS2-VASc score of ≥ 3&#xD;
&#xD;
          4. Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral&#xD;
             anticoagulation&#xD;
&#xD;
          5. Deemed by investigator to be suitable for short term oral anticoagulation therapy but&#xD;
             deemed less favorable for long-term oral anticoagulation&#xD;
&#xD;
          6. Deemed appropriate for LAA closure by the site investigator and a clinician not a part&#xD;
             of the procedural team using a shared decision-making process in accordance with&#xD;
             standard of care&#xD;
&#xD;
          7. Able to comply with the protocol-specified medication regimen and follow-up&#xD;
             evaluations&#xD;
&#xD;
          8. The patient (or legally authorized representative, where allowed) has been informed of&#xD;
             the nature of the study, agrees to its provisions, and has provided written informed&#xD;
             consent approved by the appropriate institutional review board (IRB)/Regional Ethics&#xD;
             Board (REB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing patients and those who plan pregnancy in the period up to one year&#xD;
             following the index procedure. Female patients of childbearing potential must have a&#xD;
             negative pregnancy test (per site standard test) within 7 days prior to index&#xD;
             procedure.&#xD;
&#xD;
          2. Anatomic conditions that would prevent performance of an LAA occlusion procedure&#xD;
             (e.g., prior atrial septal defect [ASD] or patent foramen ovale [PFO], surgical repair&#xD;
             or implanted closure device, or obliterated or ligated left atrial appendage)&#xD;
&#xD;
          3. Atrial fibrillation that is defined by a single occurrence or that is transient or&#xD;
             reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma,&#xD;
             recent major surgical procedures)&#xD;
&#xD;
          4. A medical condition (other than atrial fibrillation) that mandates long-term oral&#xD;
             anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary&#xD;
             embolism, or mechanical heart valve)&#xD;
&#xD;
          5. History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and/or&#xD;
             anticoagulant therapy is contraindicated&#xD;
&#xD;
          6. Documented active infection&#xD;
&#xD;
          7. Symptomatic carotid artery disease (defined as &gt;50% stenosis with symptoms of&#xD;
             ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral&#xD;
             hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or&#xD;
             endarterectomy the subject is eligible if there is &lt;50% stenosis noted at the site of&#xD;
             prior treatment&#xD;
&#xD;
          8. Recent (within 30 days of index procedure) or planned (within 60 days post-procedure)&#xD;
             cardiac or non-cardiac interventional or surgical procedure&#xD;
&#xD;
          9. Recent (within 30 days of index procedure) stroke or transient ischemic attack&#xD;
&#xD;
         10. Recent (within 30 days of index procedure) myocardial infarction&#xD;
&#xD;
         11. Vascular access precluding delivery of implant with catheter-based system&#xD;
&#xD;
         12. Severe heart failure (New York Heart Association Class IV)&#xD;
&#xD;
         13. Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral&#xD;
             valve intervention, or any mechanical valve implant&#xD;
&#xD;
         14. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) &lt;30&#xD;
             mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation)&#xD;
&#xD;
         15. Platelet count &lt;75,000 cells/mm3 or &gt;700,000 cells/mm3, or white blood cell count&#xD;
             &lt;3,000 cells/mm3&#xD;
&#xD;
         16. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device&#xD;
             materials (e.g., nickel, titanium) or that would preclude any P2Y12 inhibitor therapy,&#xD;
             or the patient has contrast sensitivity that cannot be adequately pre-medicated&#xD;
&#xD;
         17. Actively enrolled or plans to enroll in a concurrent clinical study in which the&#xD;
             active treatment arm may confound the results of this trial&#xD;
&#xD;
         18. Unable to undergo general anesthesia&#xD;
&#xD;
         19. Known other medical illness or known history of substance abuse that may cause&#xD;
             non-compliance with the protocol or protocol-specified medication regimen, confound&#xD;
             the data interpretation, or is associated with a life expectancy of less than 5 years&#xD;
&#xD;
         20. A condition which precludes adequate transesophageal echocardiographic assessment&#xD;
&#xD;
        Echo exclusion criteria:&#xD;
&#xD;
          1. Left atrial appendage anatomy which cannot accommodate either a commercially available&#xD;
             control device or the CLAAS device per manufacturer IFU (e.g., the anatomy and sizing&#xD;
             must be appropriate for both devices in order to be enrolled in the trial)&#xD;
&#xD;
          2. Intracardiac thrombus or dense spontaneous echo contrast consistent with thrombus, as&#xD;
             visualized by TEE prior to implant&#xD;
&#xD;
          3. Left ventricular ejection fraction (LVEF) &lt;30%&#xD;
&#xD;
          4. Existing circumferential pericardial effusion &gt;5 mm or symptomatic pericardial&#xD;
             effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade&#xD;
             physiology&#xD;
&#xD;
          5. Atrial septal defect that warrants closure&#xD;
&#xD;
          6. High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (exclusion&#xD;
             &gt;15 mm or length &gt; 15 mm) or large shunt (early [within 3 beats] and/or substantial&#xD;
             passage of bubbles, e.g., &gt;20)&#xD;
&#xD;
          7. Moderate or severe mitral valve stenosis (mitral valve area &lt;1.5 cm2)&#xD;
&#xD;
          8. Complex atheroma with mobile plaque of the descending aorta and/or aortic arch&#xD;
&#xD;
          9. Evidence of cardiac tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karis Oasan, MS</last_name>
    <phone>603-361-8440</phone>
    <email>koasan@conformalmedical.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

